BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21682116)

  • 1. Müllerian and mesothelial lymph node involvement in patients with borderline ovarian tumors.
    Eltabbakh GH; Mount SL
    J Reprod Med; 2011; 56(5-6):211-8. PubMed ID: 21682116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic serous borderline ovarian tumor in an internal mammary lymph node: a case report and review of the literature.
    Chamberlin MD; Eltabbakh GH; Mount SL; Leavitt BJ
    Gynecol Oncol; 2001 Jul; 82(1):212-5. PubMed ID: 11426990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.
    Alvarez AA; Moore WF; Robboy SJ; Bentley RC; Gumbs C; Futreal PA; Berchuck A
    Gynecol Oncol; 2001 Feb; 80(2):201-6. PubMed ID: 11161860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor).
    Kadar N; Krumerman M
    Gynecol Oncol; 1995 Dec; 59(3):394-7. PubMed ID: 8522262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histochemical analysis of estrogen and progesterone receptors and gastric-type mucin in mucinous ovarian tumors with reference to their pathogenesis.
    Shiohara S; Shiozawa T; Shimizu M; Toki T; Ishii K; Nikaido T; Fujii S
    Cancer; 1997 Sep; 80(5):908-16. PubMed ID: 9307191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperplastic mesothelial cells within abdominal lymph nodes: mimic of metastatic ovarian carcinoma and serous borderline tumor--a report of two cases associated with ovarian neoplasms.
    Clement PB; Young RH; Oliva E; Sumner HW; Scully RE
    Mod Pathol; 1996 Sep; 9(9):879-86. PubMed ID: 8878019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian tumours: a study of 282 cases.
    Pilli GS; Suneeta KP; Dhaded AV; Yenni VV
    J Indian Med Assoc; 2002 Jul; 100(7):420, 423-4, 447. PubMed ID: 12674165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
    Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
    Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
    Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
    Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Benign epithelial inclusions in pelvic lymph nodes. 2 case reports].
    Alvarado Cabrero I; Sosa Romero A
    Ginecol Obstet Mex; 2000 Feb; 68():77-81. PubMed ID: 10774109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors.
    Takeshima N; Hirai Y; Umayahara K; Fujiwara K; Takizawa K; Hasumi K
    Gynecol Oncol; 2005 Nov; 99(2):427-31. PubMed ID: 16112718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2010 Jan; 34(1):1-9. PubMed ID: 19898226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Evaluation of Frozen Section and Lymph Node Dissection Results for Mucinous Ovarian Tumors.
    Moroney MR; Post MD; Berning AA; Sheeder J; Corr BR
    Int J Gynecol Cancer; 2018 Jan; 28(1):92-98. PubMed ID: 29194190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis.
    Rutgers JL; Scully RE
    Cancer; 1988 Jan; 61(2):340-8. PubMed ID: 3334969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial ovarian tumors in adolescents: a retrospective pathologic study and a critical review of the literature.
    Grapsa D; Kairi-Vassilatou E; Kleanthis C; Dastamani C; Fillipidou A; Kondi-Pafiti A
    J Pediatr Adolesc Gynecol; 2011 Dec; 24(6):386-8. PubMed ID: 21945630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive immunohistochemical analysis of the gastrointestinal and Müllerian phenotypes of 139 ovarian mucinous cystadenomas.
    Halimi SA; Maeda D; Ushiku-Shinozaki A; Goto A; Oda K; Osuga Y; Fujii T; Ushiku T; Fukayama M
    Hum Pathol; 2021 Mar; 109():21-30. PubMed ID: 33275953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pathology of and controversial aspects of ovarian borderline tumours.
    McCluggage WG
    Curr Opin Oncol; 2010 Sep; 22(5):462-72. PubMed ID: 20531187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytology of ovarian epithelial tumors].
    Otsuki T; Yaegashi N
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():503-6. PubMed ID: 15535296
    [No Abstract]   [Full Text] [Related]  

  • 20. The investigation of the factors affecting retroperitoneal lymph node metastasis in stage IIIC and IV epithelial ovarian cancer.
    Yavuzcan A; Baloglu A; Cetinkaya B
    Arch Gynecol Obstet; 2009 Dec; 280(6):939-44. PubMed ID: 19306011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.